CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Because most patients with R/M NPC have received long-term maintenance of immunotherapy at
the time of initial treatment and the first-line treatment, there are a large number of PD-1
inhibitor refractory patients. How to deal with the ICIs resistance is an urgent problem in
clinical practice.